Differential evaluation of autoimmune liver disease of unknown etiology, especially autoimmune hepatitis (AIH) of childhood onset. Use in combination with Liver Cytosolic Antigen Type 1 (LC-1) Antibody, IgG (2010711) when evaluating for AIH-2.
Semi-Quantitative Indirect Fluorescent Antibody
Serum separator tube.
Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Severely hemolyzed or lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Less than 1:20 Normal
Liver-Kidney Microsome IgG antibody (anti-LKM), as detected by indirect immunofluorescent antibody (IFA) techniques, may be observed in patients with autoimmune hepatitis type 2 (AIH-2), AIH-2 associated with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), viral hepatitis C or D, and some forms of drug-induced hepatitis. This IFA does not differentiate among the four types of LKM antibodies (LKM-1, LKM-2, LKM-3, and a fourth type that recognizes CYP1A2 and CYP2A6 antigens). Of these, anti-LKM-1 (cytochrome P450IID6) IgG antibodies are considered specific for AIH-2.
Compliance Statement D: For laboratory tests using a manufactured RUO kit. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
|Component Test Code*||Component Chart Name||LOINC|
|0099270||Liver-Kidney-Microsome Abs, IgG by IFA||9838-4|
- Liver-Kidney Microsome antibody, IgG IFA
- Liver-Kidney Microsome antibody, IgG IIF
- LKM antibody, IgG IFA
- LKM antibody, IgG IIF
- LKM IgG IFA
- LKM IgG IIF